Data from the Austrian Breast & Colorectal Cancer Research Group.

The most recent long-term data, at 84 months after treatment, exposed a 28 % decreased risk for recurrence and a 36 % reduction in risk for death among sufferers treated with zoledronic acid. Also, no sufferers experienced osteonecrosis of the jaw or renal failure – thus, Gnant stated, proving the security of the procedure seven years later. Researchers also found that patients aged over the age of 40 years with presumed comprehensive ovarian blockade acquired a 34 % reduced risk for recurrence and a 44 % decreased risk for death.AcelRx forecasts that quarterly R&D expenditures through the finish of 2014 will end up being relatively consistent across all quarters with total R&D expenses likely to be in the number of $27 to $29 million for the year. Additionally, AcelRx anticipates administrative and general expenses, excluding product sales and marketing costs, will increase gradually one fourth over quarter in 2014 as the business builds infrastructure to support Zalviso's business activities. Conference Contact AcelRx will conduct a conference call and webcast today, March 3, 2014 at 4:30 p.m. Eastern time to discuss its financial outcomes and program improvements. To listen to the meeting call, dial in approximately ten minutes before the scheduled contact to 870-4263 for domestic callers, 669-9657 for Canadian callers, or 317-0790 for international callers.